Abstract:Background: Gallbladder cancer (GBC) is often diagnosed at an advanced stage with limited therapeutic options and poor prognosis. The five-year survival rate of this cancer when diagnosed at an advanced stage is below 5%, and the median survival time is less than a year with standard gemcitabine-based chemotherapy. Survival benefit with second-line treatment is unknown. Thus, there is an urgent need for novel treatment strategies and targeted therapy based on next generation sequencing (NGS) may be of value. Methods: Comprehensive genomic profiling (CGP) was performed with NGS panel on paraffin-embedded tumors from a cohort of 108 Chinese and 107 US GBC patients. Clinical data were collected using an IRB approved protocol from a single-center in US and from China. Results: In Chinese and US GBC cohorts, an average of 6.4 vs. 3.8 genomic alterations (GAs) were identified per patient. The most frequent alterations were TP53 (69.4%), CDKN2A/B (26%), ERBB2 (18.5%), PIK3CA (17%) and CCNE1 (13%) in Chinese cohort, TP53 (57.9%), CDKN2A/B (25%), SMAD4 (17%), ARID1A (14%), PIK3CA (14%) and ERBB2 (13.1%) in US patients. NFE2L2 mutations were present in 6.5% of Chinese patients and not observed in the US cohort. Interestingly, ERBB2 genetic aberrations were significantly associated with better pathological tumor differentiation and tended to co-occurrence with CDKN2A/B mutations in both the Chinese and US GBC cases. Out of the top 9 dysregulated genetic pathways in cancer, Chinese patients harbored more frequent mutations in ERBB genes (30.6% vs. 19.0%, P=0.04). High frequency of PI3K/mTOR pathway variations was observed in both Chinese (37%) and US cohort (33%) (P=0.5). Additionally, both Chinese and US GBC patients exhibited a relatively high tumor mutational burden (TMB) (17.6% and 17.0%, respectively). In the Chinese cohort, a significant association was seen between direct repair gene alterations and TMB ≥10 muts/Mb (P=0.004). Conclusions: In our study, over 83% Chinese and 68% US GBC patients had actionable alterations that could potentially guide and influence personalized treatment options. The identification of high TMB, ERBB2, CDKN2A/B, PI3K/mTOR pathway and DNA repair mutations indicated that both Chinese and US GBC patients may benefit from targeted or immune checkpoint inhibitors.

Identification of a novel heterozygous germline <i>RAD52</i> missense mutation in a patient with gallbladder carcinoma A case report

Functional Analysis of Patient-Derived PALB2 Missense Variants of Uncertain Significance.

Targeted gene sequencing and bioinformatics analysis of patients with gallbladder neuroendocrine carcinoma: A case report

Identification of a Novel Germline BRCA2 Variant in a Chinese Breast Cancer Family

Functional consequences of a rare missense BARD1 c.403G>A germline mutation identified in a triple-negative breast cancer patient

Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation

Targeted-gene Sequencing of an Undifferentiated Gallbladder Carcinoma: a Case Report.

Whole-exome and Targeted Gene Sequencing of Gallbladder Carcinoma Identifies Recurrent Mutations in the ErbB Pathway

A Multi-Institutional Investigation Assessing Prevalence of Germline Genetic Alterations in Chinese Patients with Gastric Carcinoma.

Case report: A germline CHEK1 c.613 + 2T>C leads to a splicing error in a family with multiple cancer patients

Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings

A Novel Germline Mutation of BRCA1 and Integrated Analysis with Somatic Mutation in a Chinese Multi-Cancer Family.

Clinical and genetic characterization of cancer patients with multiple germline variants.

Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients

Identification and Functional Analysis of a Novel Germ-Line Mutation in Hmsh2 from a Chinese Hereditary Non-Polyposis Colorectal Cancer Family

Clinical characteristics and genetic analysis of a case of a patient with familial hereditary breast cancer: a case report

Co-occurrence of germline pathogenic variants in Chinese patients with solid tumors.

Two Novel Germline Mutations of MLH1 and Investigation of Their Pathobiology in Hereditary Non-Polyposis Colorectal Cancer Families in China.

Germline heterozygous exons 8-11 pathogenic BARD1 gene deletion reported for the first time in a family with suspicion of a hereditary colorectal cancer syndrome: more than an incidental finding?

The E545K Mutation of PIK3CA Promotes Gallbladder Carcinoma Progression Through Enhanced Binding to EGFR.

Meta-signature of Mutated Genes in Gallbladder Cancer: Evidence Based High Throughput Screening Assays.